Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 108

1.

Strong cytotoxic effect of the bradykinin antagonist BKM-570 in ovarian cancer cells--analysis of the molecular mechanisms of its antiproliferative action.

Jutras S, Bachvarova M, Keita M, Bascands JL, Mes-Masson AM, Stewart JM, Gera L, Bachvarov D.

FEBS J. 2010 Dec;277(24):5146-60. doi: 10.1111/j.1742-4658.2010.07928.x. Epub 2010 Nov 16. Erratum in: FEBS J. 2011 Apr;278(6):999. Gera, Lajos [added].

2.

Combination cancer chemotherapy with one compound: pluripotent bradykinin antagonists.

Stewart JM, Gera L, Chan DC, York EJ, Simkeviciene V, Bunn PA Jr, Taraseviciene-Stewart L.

Peptides. 2005 Aug;26(8):1288-91.

PMID:
15878795
3.

Acquisition of chemoresistance and EMT phenotype is linked with activation of the endothelin A receptor pathway in ovarian carcinoma cells.

Rosanò L, Cianfrocca R, Spinella F, Di Castro V, Nicotra MR, Lucidi A, Ferrandina G, Natali PG, Bagnato A.

Clin Cancer Res. 2011 Apr 15;17(8):2350-60. doi: 10.1158/1078-0432.CCR-10-2325. Epub 2011 Jan 10.

5.

Bortezomib-mediated expression of p27Kip1 through S-phase kinase protein 2 degradation in epithelial ovarian cancer.

Uddin S, Ahmed M, Hussain AR, Jehan Z, Al-Dayel F, Munkarah A, Bavi P, Al-Kuraya KS.

Lab Invest. 2009 Oct;89(10):1115-27. doi: 10.1038/labinvest.2009.75. Epub 2009 Jul 27.

6.

Sensitization of p53-mutated epithelial ovarian cancer to CD95-mediated apoptosis is synergistically induced by cisplatin pretreatment.

Bagnoli M, Balladore E, Luison E, Alberti P, Raspagliesi F, Marcomini B, Canevari S, Mezzanzanica D.

Mol Cancer Ther. 2007 Feb;6(2):762-72.

7.

Bradykinin-related compounds as new drugs for cancer and inflammation.

Stewart JM, Gera L, Chan DC, Bunn PA Jr, York EJ, Simkeviciene V, Helfrich B.

Can J Physiol Pharmacol. 2002 Apr;80(4):275-80.

PMID:
12025961
8.

Suppression of annexin A11 in ovarian cancer: implications in chemoresistance.

Song J, Shih IeM, Chan DW, Zhang Z.

Neoplasia. 2009 Jun;11(6):605-14, 1 p following 614.

9.

Characterizations of irofulven cytotoxicity in combination with cisplatin and oxaliplatin in human colon, breast, and ovarian cancer cells.

Serova M, Calvo F, Lokiec F, Koeppel F, Poindessous V, Larsen AK, Laar ES, Waters SJ, Cvitkovic E, Raymond E.

Cancer Chemother Pharmacol. 2006 Apr;57(4):491-9. Epub 2005 Aug 2.

PMID:
16075278
10.

Patterns of expression of chromosome 17 genes in primary cultures of normal ovarian surface epithelia and epithelial ovarian cancer cell lines.

Presneau N, Mes-Masson AM, Ge B, Provencher D, Hudson TJ, Tonin PN.

Oncogene. 2003 Mar 13;22(10):1568-79.

PMID:
12629520
11.

DNA damage inducible-gene expression following platinum treatment in human ovarian carcinoma cell lines.

Delmastro DA, Li J, Vaisman A, Solle M, Chaney SG.

Cancer Chemother Pharmacol. 1997;39(3):245-53.

PMID:
8996528
12.

Ganoderma lucidum exerts anti-tumor effects on ovarian cancer cells and enhances their sensitivity to cisplatin.

Zhao S, Ye G, Fu G, Cheng JX, Yang BB, Peng C.

Int J Oncol. 2011 May;38(5):1319-27. doi: 10.3892/ijo.2011.965. Epub 2011 Mar 8.

PMID:
21399867
13.

A rationally designed histone deacetylase inhibitor with distinct antitumor activity against ovarian cancer.

Yang YT, Balch C, Kulp SK, Mand MR, Nephew KP, Chen CS.

Neoplasia. 2009 Jun;11(6):552-63, 3 p following 563.

14.

Global gene expression analysis of early response to chemotherapy treatment in ovarian cancer spheroids.

L'Espérance S, Bachvarova M, Tetu B, Mes-Masson AM, Bachvarov D.

BMC Genomics. 2008 Feb 26;9:99. doi: 10.1186/1471-2164-9-99.

15.

Silencing expression of UO-44 (CUZD1) using small interfering RNA sensitizes human ovarian cancer cells to cisplatin in vitro.

Leong CT, Ong CK, Tay SK, Huynh H.

Oncogene. 2007 Feb 8;26(6):870-80. Epub 2006 Jul 24.

PMID:
16862170
16.

Altered ErbB receptor signaling and gene expression in cisplatin-resistant ovarian cancer.

Macleod K, Mullen P, Sewell J, Rabiasz G, Lawrie S, Miller E, Smyth JF, Langdon SP.

Cancer Res. 2005 Aug 1;65(15):6789-800.

17.

Microarray analysis of gene expression mirrors the biology of an ovarian cancer model.

Tonin PN, Hudson TJ, Rodier F, Bossolasco M, Lee PD, Novak J, Manderson EN, Provencher D, Mes-Masson AM.

Oncogene. 2001 Oct 4;20(45):6617-26.

18.
19.

Gene expression profiling of advanced ovarian cancer: characterization of a molecular signature involving fibroblast growth factor 2.

De Cecco L, Marchionni L, Gariboldi M, Reid JF, Lagonigro MS, Caramuta S, Ferrario C, Bussani E, Mezzanzanica D, Turatti F, Delia D, Daidone MG, Oggionni M, Bertuletti N, Ditto A, Raspagliesi F, Pilotti S, Pierotti MA, Canevari S, Schneider C.

Oncogene. 2004 Oct 21;23(49):8171-83.

PMID:
15377994
20.

Characterization of DOK1, a candidate tumor suppressor gene, in epithelial ovarian cancer.

Mercier PL, Bachvarova M, Plante M, Gregoire J, Renaud MC, Ghani K, Têtu B, Bairati I, Bachvarov D.

Mol Oncol. 2011 Oct;5(5):438-53. doi: 10.1016/j.molonc.2011.07.003. Epub 2011 Jul 26.

Items per page

Supplemental Content

Write to the Help Desk